148 related articles for article (PubMed ID: 3510396)
1. Potent ulcerogenic actions of platelet-activating factor on the stomach.
Rosam AC; Wallace JL; Whittle BJ
Nature; 1986 Jan 2-8; 319(6048):54-6. PubMed ID: 3510396
[TBL] [Abstract][Full Text] [Related]
2. Effects of H1- and H2-antihistamines on platelet-activating factor and bradykinin-induced inflammatory responses in human skin.
Sansom JE; Brooks J; Burton JL; Archer CB
Clin Exp Dermatol; 1996 Jan; 21(1):33-7. PubMed ID: 8689766
[TBL] [Abstract][Full Text] [Related]
3. Platelet-activating factor and bacteremia-induced pulmonary hypertension.
Clavijo LC; Carter MB; Matheson PJ; Wills-Frank LA; Wilson MA; Wead WB; Garrison RN
J Surg Res; 2000 Feb; 88(2):173-80. PubMed ID: 10644485
[TBL] [Abstract][Full Text] [Related]
4. Platelet activating factor-induced microvascular permeability increases in the cat hindlimb.
Lu Z; Wolf MB
Circ Shock; 1993 Sep; 41(1):8-18. PubMed ID: 8403248
[TBL] [Abstract][Full Text] [Related]
5. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
[TBL] [Abstract][Full Text] [Related]
6. Picomole doses of platelet-activating factor predispose the gastric mucosa to damage by topical irritants.
Wallace JL; Whittle BJ
Prostaglandins; 1986 May; 31(5):989-98. PubMed ID: 3726156
[TBL] [Abstract][Full Text] [Related]
7. Induction of tissue injury and altered cardiovascular performance by platelet-activating factor: relevance to multiple systems organ failure.
Lefer AM
Crit Care Clin; 1989 Apr; 5(2):331-52. PubMed ID: 2650821
[TBL] [Abstract][Full Text] [Related]
8. The role of platelet-activating factor in conscious, normotensive endotoxemia.
Ephgrave K; Kremer T; Broadhurst K; Cullen J
J Surg Res; 1997 Mar; 68(2):170-4. PubMed ID: 9184676
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.
Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1987 Jun; 241(3):974-81. PubMed ID: 3598913
[TBL] [Abstract][Full Text] [Related]
10. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.
Hwang SB; Li CL; Lam MH; Shen TY
Lab Invest; 1985 Jun; 52(6):617-30. PubMed ID: 3925239
[TBL] [Abstract][Full Text] [Related]
11. Effects of a platelet-activating factor antagonist, CV-3988, on different shock models in the rat.
Toth PD; Mikulaschek AW
Circ Shock; 1986; 20(3):193-203. PubMed ID: 3802423
[TBL] [Abstract][Full Text] [Related]
12. CNS effects of platelet-activating factor on the rat stomach.
Cucala M; Wallace JL; Salas A; Guarner F; Rodríguez R; Malagelada JR
Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():67-71. PubMed ID: 2725123
[TBL] [Abstract][Full Text] [Related]
13. The inflammatory actions of platelet activating factor are blocked by levorotatory terbutaline.
Dobbins DE; Buehn MJ; Dabney JM
Microcirc Endothelium Lymphatics; 1990 Dec; 6(6):437-55. PubMed ID: 1965987
[TBL] [Abstract][Full Text] [Related]
14. Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Effects of three platelet-activating factor antagonists.
Wallace JL; Steel G; Whittle BJ; Lagente V; Vargaftig B
Gastroenterology; 1987 Oct; 93(4):765-73. PubMed ID: 3305134
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the platelet activating factor (PAF)-induced in vivo responses in rats by trans-2,5-(3,4,5-trimethoxyphenyl) tetrahydrofuran (L-652,731), a PAF receptor antagonist.
Wu MS; Biftu T; Doebber TW
J Pharmacol Exp Ther; 1986 Dec; 239(3):841-5. PubMed ID: 3795043
[TBL] [Abstract][Full Text] [Related]
16. Platelet-activating factor in septic shock.
Koltai M; Hosford D; Braquet PG
New Horiz; 1993 Feb; 1(1):87-95. PubMed ID: 7922397
[TBL] [Abstract][Full Text] [Related]
17. Role of neutrophils in gastric damage induced by platelet activating factor.
Etienne A; Thonier F; Hecquet F; Braquet P
Naunyn Schmiedebergs Arch Pharmacol; 1988 Oct; 338(4):422-5. PubMed ID: 3244384
[TBL] [Abstract][Full Text] [Related]
18. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
Terashita Z; Imura Y; Takatani M; Tsushima S; Nishikawa K
J Pharmacol Exp Ther; 1987 Jul; 242(1):263-8. PubMed ID: 3612533
[TBL] [Abstract][Full Text] [Related]
19. Release of platelet-activating factor in human pathology. I. Evidence for the occurrence of basophil degranulation and release of platelet-activating factor in systemic lupus erythematosus.
Camussi G; Tetta C; Coda R; Benveniste J
Lab Invest; 1981 Mar; 44(3):241-51. PubMed ID: 7464048
[TBL] [Abstract][Full Text] [Related]
20. Endothelin has potent ulcerogenic and vasoconstrictor actions in the stomach.
Wallace JL; Cirino G; De Nucci G; McKnight W; MacNaughton WK
Am J Physiol; 1989 Apr; 256(4 Pt 1):G661-6. PubMed ID: 2650567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
